OBJECTIVES: To investigate the relationships between episodic memory, APOE genotype, CSF markers (total tau, T-tau; phospho-tau, P-tau; beta-amyloid, Abeta42) and longitudinal cognitive decline. METHODS: 124 memory clinic patients were retrospectively divided into 6 groups based on (i) episodic memory function (Rey Auditory Verbal Learning Test, RAVLT): severe, moderate or no impairment (SIM, MIM or NIM), and (ii) APOE genotype (epsilon4+ or epsilon4-). CSF marker levels and cognitive decline were compared across groups. RESULTS: Episodic memory function, according to RAVLT scores, was significantly correlated with CSF marker levels only among epsilon4+ subjects and not among epsilon4- subjects. When comparing the 6 subgroups, SIM epsilon4+ and MIM epsilon4+ groups showed significantly lower Abeta42 levels than the other groups. T-tau and P-tau levels were significantly increased in SIM epsilon4+ when compared to all the other groups, including the SIM epsilon4- group. However, both SIM epsilon4+ and SIM epsilon4- declined cognitively during the follow-up. CONCLUSION: It remains to be determined whether APOE genotype affects the expression of biomarkers in CSF, or whether the different biomarker patterns reflect different types of disease processes in patients with progressive cognitive dysfunction. Copyright (c) 2007 S. Karger AG, Basel.
OBJECTIVES: To investigate the relationships between episodic memory, APOE genotype, CSF markers (total tau, T-tau; phospho-tau, P-tau; beta-amyloid, Abeta42) and longitudinal cognitive decline. METHODS: 124 memory clinic patients were retrospectively divided into 6 groups based on (i) episodic memory function (Rey Auditory Verbal Learning Test, RAVLT): severe, moderate or no impairment (SIM, MIM or NIM), and (ii) APOE genotype (epsilon4+ or epsilon4-). CSF marker levels and cognitive decline were compared across groups. RESULTS:Episodic memory function, according to RAVLT scores, was significantly correlated with CSF marker levels only among epsilon4+ subjects and not among epsilon4- subjects. When comparing the 6 subgroups, SIM epsilon4+ and MIM epsilon4+ groups showed significantly lower Abeta42 levels than the other groups. T-tau and P-tau levels were significantly increased in SIM epsilon4+ when compared to all the other groups, including the SIM epsilon4- group. However, both SIM epsilon4+ and SIM epsilon4- declined cognitively during the follow-up. CONCLUSION: It remains to be determined whether APOE genotype affects the expression of biomarkers in CSF, or whether the different biomarker patterns reflect different types of disease processes in patients with progressive cognitive dysfunction. Copyright (c) 2007 S. Karger AG, Basel.
Authors: Duygu Tosun; Norbert Schuff; Diana Truran-Sacrey; Leslie M Shaw; John Q Trojanowski; Paul Aisen; Ronald Peterson; Michael W Weiner Journal: Neurobiol Aging Date: 2010-06-08 Impact factor: 4.673
Authors: Anders M Fjell; Kristine B Walhovd; Christine Fennema-Notestine; Linda K McEvoy; Donald J Hagler; Dominic Holland; Kaj Blennow; James B Brewer; Anders M Dale Journal: Cereb Cortex Date: 2010-01-04 Impact factor: 5.357
Authors: F W Sabb; A C Burggren; R G Higier; J Fox; J He; D S Parker; R A Poldrack; W Chu; T D Cannon; N B Freimer; R M Bilder Journal: Neuroscience Date: 2009-05-18 Impact factor: 3.590
Authors: A M Fjell; K B Walhovd; I Amlien; A Bjørnerud; I Reinvang; L Gjerstad; T Cappelen; F Willoch; P Due-Tønnessen; R Grambaite; A Skinningsrud; V Stenset; T Fladby Journal: AJNR Am J Neuroradiol Date: 2008-06 Impact factor: 3.825
Authors: Craig Ritchie; Nadja Smailagic; Anna H Noel-Storr; Yemisi Takwoingi; Leon Flicker; Sam E Mason; Rupert McShane Journal: Cochrane Database Syst Rev Date: 2014-06-10